CAC 40
7 321,44 -24,71 (-0,34 %) Euro Stoxx 50
4 411,64 -6,87 (-0,16 %) Dow Jones
36 245,50 +294,60 (+0,82 %) EUR/USD
1,0851 -0,0034 (-0,31 %) Gold future
2 078,00 -11,70 (-0,56 %) Bitcoin EUR
38 497,54 +1 885,02 (+5,15 %)
MRK Jan 2025 90.000 call
| Clôture précédente | 17,25 |
| Ouverture | 17,25 |
| Offre | 0,00 |
| Vente | 0,00 |
| Prix d’exercice | 90,00 |
| Date d’expiration | 2025-01-17 |
| Var. jour | 17,25 - 17,25 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 269 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
